Riskpilot← Back to searchSign inGet full accessEläinklinikka Saari Oy
OYActiveY-tunnus 0708667-9Gerbyntie 1822Veterinary activities · NACE 7500Est. 1988— employees
Revenue 2024
EUR 0
EBITDA margin
—
-27% vs 2023
Equity ratio
57.1%
Financial strength
Net profit 2024
EUR 23K
-46% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR 69K | -27% |
| Net profit | EUR 23K | -46% |
| Total assets | EUR 417K | +0% |
| Equity | EUR 238K | +2% |
| Employees | — | — |
Legal name
Eläinklinikka Saari Oy
Y-tunnus number
0708667-9
Legal form
Osakeyhtiö
NACE code
7500 · Veterinary activities
Founded
29. elokuuta 1988
Share capital
EUR 5 046
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Yhtiön toimialana on eläinlääkintä ja -hoito, eläinlääkintätarvikkeiden tuonti, vienti ja markkinointi, laboratoriopalvelut. Em. toimintaan liittyvä neuvonta ja konsultointi. Yhtiöllä on oikeus omistaa kiinteistöjä, osakkeita ja osuuksia.
Address
Gerbyntie 1822
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 936 | 954 | 1 033 | 0 | 0 |
| Staff expenses | −437 | −486 | −542 | −0 | −0 |
| EBITDA | 120 | 64 | 90 | 94 | 69 |
| Depreciation & amort. | −38 | −47 | −39 | −39 | −40 |
| EBIT | 81 | 16 | 51 | 55 | 29 |
| Net financials | −1 | −1 | −1 | −1 | −0 |
| Profit before tax | 80 | 15 | 50 | 54 | 29 |
| Tax | 16 | 3 | 10 | 11 | 6 |
| Net profit | 64 | 13 | 40 | 43 | 23 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 350 | 345 | 390 | 416 | 417 |
| Equity | 198 | 194 | 219 | 233 | 238 |
| Long-term debt | 47 | 31 | 15 | 0 | 0 |
| Short-term debt | 105 | 119 | 156 | 178 | 179 |
| Total debt | 152 | 150 | 171 | 182 | 179 |
EBITDA margin
6900900.0%
This company
15.8%
Market median
+43676482% vs market
20202024
Equity ratio
57.1%
This company
38.2%
Market median
+49% vs market
20202024
Return on equity
9.8%
This company
18.4%
Market median
-47% vs market
20202024
Net profit margin
2335300.0%
This company
8.1%
Market median
+28830764% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.75×
This company
0.62×
Market median
+21% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
HM Deputy Member | Deputy Member | 2018 |
PS Chief Executive Officer | Chief Executive Officer | 2018 |
JF Audit | Audit | 2004 |
SR Deputy auditor | Deputy auditor | 2025 |
| Former (1) | ||
HM Deputy auditor | Deputy auditor | 2004 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Eläinklinikka Saari Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Harry Mikael Kvarngård | Deputy Member | 0 companies |
| Pamela Sofia Kvarngård | Chief Executive Officer | 0 companies |
| Johan-Erik Fant | Audit | 0 companies |
| Håkan Mats Tage Vest | Deputy auditor | 0 companies |
| Stefan Rolf Axel Wiklund | Deputy auditor | 0 companies |
| Assaf Wydra | Board of Directors | 0 companies |